companies / cuebiopharma-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-21 json
| total_raised | 29,999,99230.0M | ○ |
|---|---|---|
| founded | 2014 | |
| hq | Boston, MA | |
| industry | unknown | |
| stage | null |
Cue Biopharma is a clinical-stage precision immunology company developing biologics aimed at functional cures for immune disorders with high unmet need. It targets patients with autoimmune conditions that current therapies only manage. Its approach modulates the specific immune cells driving disease rather than broadly suppressing immunity.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-05-04 | Funding round | 29,999,99230.0M | null | ○ |
Nginx, WordPress, Modernizr, Yoast SEO 23.4, Google Analytics, Google Tag Manager, Site Kit 1.179.0, jQuery Migrate 3.4.1, DoubleClick Floodlight, WordPress Block Editor, WP Engine, MongoDB
| fact | status | src |
|---|---|---|
| Funding round, $30.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $30.0M, 2026-05-04 → Funding round, $30.0M, 2026-05-04, ○ 2026-05-21 | latest_round | seed, $30.0M, 2026-05-04 → Funding round, $30.0M, 2026-05-04 | ○ 2026-05-21 |
Records begin 2026-09-24. all_changes